These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30314604)

  • 1. Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease.
    Ghadery C; Valli M; Mihaescu A; Strafella R; Navalpotro I; Kim J; Strafella AP
    Int Rev Neurobiol; 2018; 141():365-404. PubMed ID: 30314604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
    Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
    Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review.
    Béreau M; Fleury V; Bouthour W; Castrioto A; Lhommée E; Krack P
    Rev Neurol (Paris); 2018 Nov; 174(9):653-663. PubMed ID: 30224159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging and neural networks in impulse control disorders in Parkinson's disease.
    Aracil-Bolaños I; Strafella AP
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S101-5. PubMed ID: 26298389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unmasking neurobiological commonalities between addictive disorders and impulse control disorders in Parkinson's disease.
    Ramdave S; Dawson A; Carter A; Dissanayaka NNW
    Brain Imaging Behav; 2020 Dec; 14(6):2785-2798. PubMed ID: 30707344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Imaging of Opioid System in Idiopathic Parkinson's Disease.
    Thobois S; Brefel-Courbon C; Le Bars D; Sgambato-Faure V
    Int Rev Neurobiol; 2018; 141():275-303. PubMed ID: 30314599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Delpont B; Lhommée E; Klinger H; Schmitt E; Bichon A; Fraix V; Castrioto A; Quesada JL; Pélissier P; Kistner A; Carnicella S; Lüscher C; Broussolle E; Pollak P; Thobois S; Krack P
    Mov Disord; 2017 Nov; 32(11):1566-1573. PubMed ID: 28737225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
    Linazaroso G; van Blercom N; Lasa A
    Neurologia; 2004 Apr; 19(3):117-27. PubMed ID: 15088161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging impulse control disorders in Parkinson's disease and their relationship to addiction.
    Ray NJ; Strafella AP
    J Neural Transm (Vienna); 2013 Apr; 120(4):659-64. PubMed ID: 23232664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.
    de Natale ER; Niccolini F; Wilson H; Politis M
    Int Rev Neurobiol; 2018; 141():131-172. PubMed ID: 30314595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic function and intertemporal choice.
    Joutsa J; Voon V; Johansson J; Niemelä S; Bergman J; Kaasinen V
    Transl Psychiatry; 2015 Jan; 5(1):e491. PubMed ID: 25562841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.
    O'Sullivan SS; Evans AH; Lees AJ
    CNS Drugs; 2009; 23(2):157-70. PubMed ID: 19173374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Corvol JC
    Bull Acad Natl Med; 2014 Oct; 198(7):1297-307; discussion 1307-8. PubMed ID: 27120903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictors and modifiers of impulse control disorders in Parkinson`s disease].
    Sapronova MR; Shnayder NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11):145-156. PubMed ID: 28635753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography in Parkinson's disease: insights into impulsivity.
    Stark AJ; Claassen DO
    Int Rev Psychiatry; 2017 Dec; 29(6):618-627. PubMed ID: 29206483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants.
    Castro-Martínez XH; García-Ruiz PJ; Martínez-García C; Martínez-Castrillo JC; Vela L; Mata M; Martínez-Torres I; Feliz-Feliz C; Palau F; Hoenicka J
    Parkinsonism Relat Disord; 2018 Apr; 49():100-103. PubMed ID: 29361389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease.
    Tessitore A; De Micco R; Giordano A; di Nardo F; Caiazzo G; Siciliano M; De Stefano M; Russo A; Esposito F; Tedeschi G
    Mov Disord; 2017 Dec; 32(12):1710-1719. PubMed ID: 28949049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders.
    Lee JY; Seo SH; Kim YK; Yoo HB; Kim YE; Song IC; Lee JS; Jeon BS
    J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):23-30. PubMed ID: 24023269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches.
    Jiménez-Urbieta H; Gago B; de la Riva P; Delgado-Alvarado M; Marin C; Rodriguez-Oroz MC
    Neurosci Biobehav Rev; 2015 Sep; 56():294-314. PubMed ID: 26216865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional brain imaging of cognitive dysfunction in Parkinson's disease.
    Hirano S; Shinotoh H; Eidelberg D
    J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):963-9. PubMed ID: 22807560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.